{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:23:09Z","timestamp":1790166189271,"version":"4.1.0"},"reference-count":91,"publisher":"Georg Thieme Verlag KG","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2013]]},"abstract":"<jats:title>summary<\/jats:title><jats:p>Clinical management of obese subjects to reduce their risk of suffering cardiovascular events is complex. Obese patients typically require preventive strategies, life-style modifications, and multi-drug therapy to address obesity-induced co-morbidities. Data regarding the effects of excess weight on the pharmacokinetics of most drugs is scarce as these individuals are often excluded from clinical trials. However, the physiological alterations observed in obese patients and their lower response to some antiplatelet agents and anticoagulants have suggested that dosage regimes need to be adjusted for these subjects. In this review we will briefly discuss platelet alterations that can contributeto increased thrombotic risk, analyse existing data regarding the effects of obesity on drug pharmacokinetics focusing on antiplatelet agents and anticoagulants, and we will describe the beneficial effects of weight loss on thrombosis.<\/jats:p>","DOI":"10.1160\/th12-12-0928","type":"journal-article","created":{"date-parts":[[2013,3,28]],"date-time":"2013-03-28T12:34:27Z","timestamp":1364474067000},"page":"681-688","source":"Crossref","is-referenced-by-count":23,"title":["Antithrombotic therapy in obesity"],"prefix":"10.1160","volume":"110","author":[{"given":"Rodrigo","family":"Hern\u00e1ndez Vera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Padr\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Vilahur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Badimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2017,12,1]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"KG Alberti","year":"2009","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jacc.2010.05.034","article-title":"The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis","volume":"56","author":"S Mottillo","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1517\/14656566.2011.585462","article-title":"Metabolic syndrome: nature, therapeutic solutions and options","volume":"12","author":"A Onat","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/01.CIR.0000017823.53114.4C","article-title":"Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on the pathophysiology of obesity-associated cardiovascular disease","volume":"105","author":"RH Eckel","year":"2002","journal-title":"Circulation"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/HPC.0b013e318057d4c9","article-title":"Cardiovascular disease under the influence of excess visceral fat","volume":"6","author":"JP Despres","year":"2007","journal-title":"Crit Pathw Cardiol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.numecd.2009.01.006","article-title":"Platelet dysfunction in central obesity","volume":"19","author":"G Anfossi","year":"2009","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1055\/s-0030-1248723","article-title":"Disorders of coagulation and hemostasis in abdominal obesity: emerging role of fatty liver","volume":"36","author":"G Targher","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2174\/1573399810602040409","article-title":"Platelet resistance to the anti-aggregating agents in the insulin resistant states","volume":"2","author":"G Anfossi","year":"2006","journal-title":"Curr Diabetes Rev"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2337\/diacare.21.1.121","article-title":"Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM","volume":"21","author":"G Anfossi","year":"1998","journal-title":"Diabetes Care"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2362.2004.01370.x","article-title":"Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity","volume":"34","author":"G Anfossi","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00125-006-0222-7","article-title":"Enhanced soluble CD40L in patients with the metabolic syndrome: Relationship with in vivo thrombin generation","volume":"49","author":"F Angelico","year":"2006","journal-title":"Diabetologia"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.numecd.2006.09.010","article-title":"sP-selectin plasma levels in obesity: association with insulin resistance and related metabolic and prothrombotic factors","volume":"18","author":"G De Pergola","year":"2008","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1210\/jc.2007-2491","article-title":"The proinflammatory mediator CD40 ligand is increased in the metabolic syndrome and modulated by adiponectin","volume":"93","author":"C Natal","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/j.1742-1241.2005.00500.x","article-title":"The mean platelet volume in patients with obesity","volume":"59","author":"E Coban","year":"2005","journal-title":"Int J Clin Pract"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/1076029607303615","article-title":"Elevated concentrations of soluble adhesion molecules and large platelets in diabetic patients: are they markers of vascular disease and diabetic nephropathy?","volume":"13","author":"N Bavbek","year":"2007","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1161\/01.STR.0000130512.81212.a2","article-title":"Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events?","volume":"35","author":"S Greisenegger","year":"2004","journal-title":"Stroke"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/138161211795049804","article-title":"Mean platelet volume: a link between thrombosis and inflammation?","volume":"17","author":"AY Gasparyan","year":"2011","journal-title":"Curr Pharm Des"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"5953","DOI":"10.1073\/pnas.86.15.5953","article-title":"Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro","volume":"86","author":"T Ishibashi","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1172\/JCI26674","article-title":"The molecular mechanisms that control thrombopoiesis","volume":"115","author":"K Kaushansky","year":"2005","journal-title":"J Clin Invest"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000083816","article-title":"Adipose tissue and atherothrombosis","volume":"33","author":"MC Alessi","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1161\/01.RES.0000163635.62927.34","article-title":"Adipose tissue, inflammation, and cardiovascular disease","volume":"96","author":"AH Berg","year":"2005","journal-title":"Circ Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0083-6729(06)74018-3","article-title":"Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells","volume":"74","author":"JN Fain","year":"2006","journal-title":"Vitam Horm"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1139\/y06-092","article-title":"Type 2 diabetes and cardiovascular disease: getting to the fat of the matter","volume":"85","author":"KB Goralski","year":"2007","journal-title":"Can J Physiol Pharmacol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.ATV.19.3.672","article-title":"A role for changes in platelet production in the cause of acute coronary syndromes","volume":"19","author":"B van der Loo","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1161\/ATVBAHA.112.255281","article-title":"Platelets derived from the bone marrow of diabetic animals show dysregulated endoplasmic reticulum stress proteins that contribute to increased thrombosis","volume":"32","author":"R Hern\u00e1ndez Vera","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1160\/TH12-09-0696","article-title":"Obesity with insulin resistance increase thrombosis in wild-type and bone marrow-transplanted Zucker fatty rats","volume":"109","author":"R Hern\u00e1ndez Vera","year":"2013","journal-title":"Thromb Haemost"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1001\/jama.282.22.2131","article-title":"Elevated C-reactive protein levels in overweight and obese adults","volume":"282","author":"M Visser","year":"1999","journal-title":"J Am Med Assoc"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1161\/ATVBAHA.108.174359","article-title":"C-reactive protein isoforms differ in their effects on thrombus growth","volume":"28","author":"B Molins","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/cvr\/cvr226","article-title":"Monomeric C-reactive protein is prothrombotic and dissociates from circulating pentameric C-reactive protein on adhered activated platelets under flow","volume":"92","author":"B Molins","year":"2011","journal-title":"Cardiovasc Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.thromres.2005.12.013","article-title":"Impact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity","volume":"119","author":"T Murakami","year":"2007","journal-title":"Thromb Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2006.08.040","article-title":"Insulin resistance as a determinant of platelet activation in obese women","volume":"48","author":"S Basili","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.288.16.2008","article-title":"Platelet activation in obese women: role of inflammation and oxidant stress","volume":"288","author":"G Davi","year":"2002","journal-title":"J Am Med Assoc"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1517\/17425255.2012.722757","article-title":"The effects of gastric bypass surgery on drug absorption and pharmacokinetics","volume":"8","author":"DR Brocks","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/clpt.2011.104","article-title":"Implications of obesity for drug therapy: limitations and challenges","volume":"90","author":"R Jain","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"S 05","key":"ref35","doi-asserted-by":"crossref","first-page":"254S","DOI":"10.1038\/oby.2006.319","article-title":"Leptin resistance and obesity","volume":"14","author":"PJ Enriori","year":"2006","journal-title":"Obesity"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1093\/eurheartj\/ehn387","article-title":"Adipose tissue dysfunction in obesity, diabetes, and vascular diseases","volume":"29","author":"GR Hajer","year":"2008","journal-title":"Eur Heart J"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2009.07.031","article-title":"Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome","volume":"314","author":"E Maury","year":"2010","journal-title":"Mol Cell Endocrinol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"986","DOI":"10.2337\/diacare.18.7.986","article-title":"Absorption of rapid-acting insulin in obese and nonobese NIDDM patients","volume":"18","author":"PG Clauson","year":"1995","journal-title":"Diabetes Care"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1067\/mcp.2002.127114","article-title":"The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers","volume":"72","author":"GJ Sanderink","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.contraception.2010.04.016","article-title":"Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review","volume":"82","author":"AB Edelman","year":"2010","journal-title":"Contraception"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/11318100-000000000-00000","article-title":"Effect of obesity on the pharmacokinetics of drugs in humans","volume":"49","author":"MJ Hanley","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1517\/17425255.2011.570331","article-title":"The effects of obesity on drug pharmacokinetics in humans","volume":"7","author":"GA Morrish","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/js980173a","article-title":"Pharmacokinetic considerations in obesity","volume":"88","author":"RA Blouin","year":"1999","journal-title":"J Pharm Sci"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2125.2004.02157.x","article-title":"What is the best size descriptor to use for pharmacokinetic studies in the obese?","volume":"58","author":"B Green","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/11317690-000000000-00000","article-title":"Predictive performance of the \u2018Minto\u2019 remifentanil pharmacokinetic parameter set in morbidly obese patients ensuing from a new method for calculating lean body mass","volume":"49","author":"L La Colla","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s11095-009-9873-7","article-title":"Encouraging the move towards predictive population models for the obese using propofol as a motivating example","volume":"26","author":"SC McLeay","year":"2009","journal-title":"Pharm Res"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"E768","DOI":"10.1152\/ajpendo.00381.2004","article-title":"Acquired obesity is associated with increased liver fat, intra-abdominal fat, and insulin resistance in young adult monozygotic twins","volume":"288","author":"KH Pietilainen","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/sj.mn.7800206","article-title":"Impairment of hepatic microcirculation in fatty liver","volume":"10","author":"S Ijaz","year":"2003","journal-title":"Microcirculation"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1751-7141.2009.00058.x","article-title":"Effect of obesity on platelet reactivity and response to low-dose aspirin","volume":"13","author":"BC Bordeaux","year":"2010","journal-title":"Prev Cardiol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/sj.ijo.0802312","article-title":"Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects","volume":"27","author":"M Tamminen","year":"2003","journal-title":"Int J Obes Relat Metab Disord"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1161\/hq0102.101546","article-title":"Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity","volume":"22","author":"J Westerbacka","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"742","DOI":"10.2337\/diab.46.5.742","article-title":"Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine-3', 5'-cyclic monophosphate and adenosine-3', 5'-cyclic monophosphate","volume":"46","author":"M Trovati","year":"1997","journal-title":"Diabetes"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.2337\/diab.44.11.1318","article-title":"Impaired insulin-induced platelet antiaggregating effect in obesity and in obese NIDDM patients","volume":"44","author":"M Trovati","year":"1995","journal-title":"Diabetes"},{"key":"ref54","first-page":"169","article-title":"Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?","volume":"16","author":"DJ Angiolillo","year":"2004","journal-title":"J Invasive Cardiol"},{"key":"ref55","first-page":"325","article-title":"Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study","volume":"16","author":"DJ Angiolillo","year":"2004","journal-title":"J Invasive Cardiol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijcard.2006.09.014","article-title":"Clopidogrel resistance: role of body mass and concomitant medications","volume":"120","author":"G Feher","year":"2007","journal-title":"Int J Cardiol"},{"key":"ref57","first-page":"115","article-title":"The influence of body mass index on outcomes and the benefit of antiplatelet therapy following percutaneous coronary intervention","volume":"18","author":"RV Kelly","year":"2006","journal-title":"J Invasive Cardiol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1161\/CIRCULATIONAHA.104.502815","article-title":"Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial","volume":"111","author":"SD Wiviott","year":"2005","journal-title":"Circulation"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"SD Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.amjcard.2012.08.043","article-title":"Prasugrel monitoring and bleeding in real world patients","volume":"111","author":"G Cayla","year":"2013","journal-title":"Am J Cardiol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"L Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1093\/eurheartj\/ehr231","article-title":"Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes","volume":"32","author":"RF Storey","year":"2011","journal-title":"Eur Heart J"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/ccd.20622","article-title":"The relationship of obesity to ischemic outcomes following coronary stent placement in contemporary practice","volume":"67","author":"JL Martin","year":"2006","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.amjmed.2005.03.012","article-title":"Obesity as a risk factor in venous thromboembolism","volume":"118","author":"PD Stein","year":"2005","journal-title":"Am J Med"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/CIRCULATIONAHA.107.709204","article-title":"Cardiovascular risk factors and venous thromboembolism: a meta-analysis","volume":"117","author":"W Ageno","year":"2008","journal-title":"Circulation"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/sj.ejcn.1602769","article-title":"Age, period and birth cohort effects on prevalence of overweight and obesity in Australian adults from 1990 to 2000","volume":"62","author":"MA Allman-Farinelli","year":"2008","journal-title":"Eur J Clin Nutr"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1001\/archinte.168.15.1678","article-title":"Overweight, obesity, and the risk of recurrent venous thromboembolism","volume":"168","author":"S Eichinger","year":"2008","journal-title":"Arch Int Med"},{"issue":"S 06","key":"ref68","doi-asserted-by":"crossref","first-page":"381S","DOI":"10.1378\/chest.08-0656","article-title":"Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"WH Geerts","year":"2008","journal-title":"Chest"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1538-7836.2005.01342.x","article-title":"The skinny on treatment of venous thromboembolism in obesity","volume":"3","author":"SA Spinler","year":"2005","journal-title":"J Thromb Haemost"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"874","DOI":"10.7326\/0003-4819-119-9-199311010-00002","article-title":"The weight-based heparin dosing nomogram compared with a \"standard care\" nomogram. A randomized controlled trial","volume":"119","author":"RA Raschke","year":"1993","journal-title":"Ann Intern Med"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0002-8703(03)00121-2","article-title":"Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies","volume":"146","author":"SA Spinler","year":"2003","journal-title":"Am Heart J"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1538-7836.2005.01304.x","article-title":"The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE)","volume":"3","author":"R Barba","year":"2005","journal-title":"J Thromb Haemost"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1538-7836.2008.02907.x","article-title":"Body mass index and mortality in patients with acute venous thromboembolism: findings from the RIETE registry","volume":"6","author":"R Barba","year":"2008","journal-title":"J Thromb Haemost"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/archinte.165.1.55","article-title":"The obesity paradox: body mass index and outcomes in patients with heart failure","volume":"165","author":"JP Curtis","year":"2005","journal-title":"Archives of internal medicine"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.amjcard.2007.01.018","article-title":"Relation of body mass index to outcome in patients with known or suspected coronary artery disease","volume":"99","author":"W Galal","year":"2007","journal-title":"Am J Cardiol"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1001\/archinte.162.16.1833","article-title":"Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies","volume":"162","author":"AG Turpie","year":"2002","journal-title":"Arch Int Med"},{"key":"ref77","volume-title":"Pharmacokinetic properties of fondaparinux sodium in morbidly obese volunteers indicate that a single, weight-independent daily dose for thromboprophylaxis is feasible. Presented at: Society of American Gastrointestinal and Endoscopic Surgeons (SAGES)","author":"I Raftopoulos","year":"2008"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2008.12.068","article-title":"Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss","volume":"53","author":"CJ Lavie","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1177\/00033197040550i601","article-title":"Prevention and treatment of the metabolic syndrome","volume":"55","author":"SS Daskalopoulou","year":"2004","journal-title":"Angiology"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/11599000-000000000-00000","article-title":"Drug treatment of obesity in cardiovascular disease","volume":"12","author":"M Charakida","year":"2012","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2337\/diacare.23.10.1499","article-title":"Intentional weight loss and mortality among overweight individuals with diabetes","volume":"23","author":"DF Williamson","year":"2000","journal-title":"Diabetes Care"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1001\/jama.289.14.1799","article-title":"Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial","volume":"289","author":"K Esposito","year":"2003","journal-title":"J Am Med Assoc"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1210\/jc.2003-031310","article-title":"Effects of hypocaloric diet and exercise training on inflammation and adipocyte lipolysis in obese postmenopausal women","volume":"89","author":"T You","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.2337\/diacare.26.7.2119","article-title":"Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome","volume":"26","author":"O Hamdy","year":"2003","journal-title":"Diabetes Care"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.2337\/diacare.26.6.1673","article-title":"Weight loss in combination with physical activity improves endothelial dysfunction in human obesity","volume":"26","author":"A Sciacqua","year":"2003","journal-title":"Diabetes Care"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.2174\/092986711798184299","article-title":"Determinants of increased cardiovascular disease in obesity and metabolic syndrome","volume":"18","author":"N Vazzana","year":"2011","journal-title":"Curr Med Chem"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/oby.2009.302","article-title":"In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin","volume":"18","author":"I Russo","year":"2010","journal-title":"Obesity"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1055\/s-0037-1616100","article-title":"Plasma PAI-1 levels in obese children--effect of weight loss and influence of PAI-1 promoter 4G\/5G genotype","volume":"86","author":"A Estelles","year":"2001","journal-title":"Thromb Haemost"},{"key":"ref89","first-page":"85","article-title":"The influence of weight loss on fibrinolytic and metabolic parameters in obese children and adolescents","volume":"14","author":"KM Sudi","year":"2001","journal-title":"J Pediatr Endocrinol Metab"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/oby.2010.213","article-title":"Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity","volume":"19","author":"Q Wang","year":"2011","journal-title":"Obesity"},{"issue":"S 01","key":"ref92","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1038\/ijo.2011.142","article-title":"Bariatric surgery for treatment of obesity","volume":"35","author":"S Eldar","year":"2011","journal-title":"Int J Obes"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1160\/TH12-12-0928.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T11:57:44Z","timestamp":1685534264000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1160\/TH12-12-0928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":91,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,12,1]]},"published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1160\/th12-12-0928","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}